Valproate: A practical review of its uses in neurological and psychiatric disorders

Expert Review of Neurotherapeutics

Volumn 2, Issue 2, 2002, Pages 151-165

  Kanner, Andres M ^a   Balabanov, Antoaneta ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Absence seizures; Bipolar disorder; Epilepsy; Hepatic failure; Infantile spasms; Juvenile myoclonic epilepsy; Lennox Gastaut syndrome; Migraine; Neural tube defect; Pancreatitis; Panic disorder; Parenteral valproate; Partial seizure disorders

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; CIMETIDINE; ERYTHROMYCIN; LAMOTRIGINE; LORAZEPAM; NEUROLEPTIC AGENT; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE DERIVATIVE; SEROTONIN 2 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN;

DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; EPILEPSY; GASTROINTESTINAL TOXICITY; HUMAN; MENTAL DISEASE; MIGRAINE; REVIEW; SEIZURE;

EID: 0036282286     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.2.151     Document Type: Review

References (104)

1. Valproic acid: Mechanism of action
2. Mechanism of anticonvulsant action of Valproate
3. Effect of di-n-propylacerate, an anticonvulsive compound, on GABA metabolism
4. Correlation between alternations in brain GABA metabolism and seizure excitability following administration of GABA aminotransferase inhibitors and valproic acid - A reevaluation
5. An analysis of the kinetics of the inhibition rabbit GABA-transaminase by sodium N-dipropylacetate and some other simple carboxylic acids
6. The inhibitory effect of sodium n-dipropylacetate on the degenerative enzymes of the GABA shunt
7. Sodium valproate but ethosuximate, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture
8. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on the evoked changes on (CA+) and (K+) in the hippocampal shoe
9. Effect of N-dipropylacetate on amino acid concentration in mouse brain: Correlation with anticonvulsant activin
10. Disposition of sodium valproate in epileptic patients
11. Valproate
12. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance and preference
13. Meal-dependent absorption of entericcoated sodium valproate
14. Disposition of valproic in man
15. Pharmacokinetics and bioavailability of sodium valproate
16. Bioavailability of rectal administered valproic acid syrup
17. Pharmacokinetic aspects of sodium valproate suppositories
18. Rectal valproate syrup and status epilepticus
19. Absorption of valproic acid suppositories in human volunteers
20. The safety of rapid valproic infusion
21. Safety of rapid iv. infusion of valproate loading doses in epilepsy patients
22. Variable free and total valproic acid concentrations in sole- and multidrug therapy
23. The effect of aspirin on valproic acid metabolism
24. Pharmacological evaluation of various metabolites and analogues of valproic acid
25. The hepatotoxisity of valproic acid and its metabolites in rats. I. Toxocologic, biochemical and histopathologic studies
26. Valproic acid pharmacokinetics in children. Effect of age and anti-epileptic drugs on protein binding and intrinsic clearance
27. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy
28. Anti-epileptic effect of conventional anticonvulsants in the kindling model of epilepsy
29. Monotherapy with valprote in primary generalized epilepsy
30. The expert consensus guideline series. Treatment of epilepsy
31. Effect of valproic acid in epilepsy on spike and wave discharges in patients with absence seizures
32. Valproic acid-ethusuximade interaction: A pharmacokinetic study
33. Valproate and clonazepam in treatment of severe progressive myoclonus epilepsy
34. Effect of Divalproex-Lamotrigine combination therapy in frontal lobe seizures
35. Adding valproate to lamotrigine: A study of their pharmacokinetic interaction
36. Lamotrigine substitution study: Evidence for synergism with sodium valproate
37. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
38. A comparison of valproate with carbamezapine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults
39. Valproate versus carbamazepine for seizures
40. Pharmacodynamic interactions between phenytoin and valproate: Individual and combined anti-epileptic and neurotoxic actions in mice
41. Sodium valproate acutely inhibits lamotrigine metabolism
42. Lack of effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy
43. Carbamazepine/valproic acid interaction in man and rhesus monkey
44. Treatment of infantile spasms with sodium dipropylaceric acid
45. Phenobarbital-valproic acid interaction
46. The effect of felbamate on valproate disposition
47. Serum protein binding of diazepam and its displacement by valproic acid in vitro
48. Pediatric use of iv. and itramuscular phenytoin: Lessions learned
49. Intravenous loading of valproate for epilepsy
50. Comprehensive review of the psychiatric use of valproate
51. Effect of divalproex versus lithium on length of hospital stays among patients with bipolar disorder
52. Valproate treatment of panic disorder in lactate-induced panic attacks
53. Randomized, placebo-controlled pilot study of divolproex sodium in the treatment of acute exacerbations of chronic schizophrenia
54. Critical review of GABA-ergic drugs in the treatment of schizophrenia
55. Effects of divalproax sodium on aminotriptyline and nortriptyline pharmacokinetics
56. Interaction of fluoxatine an dvalproic acid
57. The effects of neuroleptics (haloperidol and chlorpromazine) on pharmacokinetics of valproic acid in schizophrenic patients
58. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium
59. Possible mechanisms of valproate in migraine prophylaxis
60. Cerebrospinal gamma-aminobutyric acid levels in migraine
61. Cerebrospinal fluid analysis in migraine patients and controls
62. Migraine prophylaxis with divalproex
63. Safety of divalproex sodium in migraine prophylaxis: An open-label, long-term study. Long-term safety of Depakote in headache prophylactic study group
64. A comparison of Divalproex with Propranolol and Placebo for the Prophylaxis of migraine without aura
65. Divalproex in long-term treatment of chronic daily headache
66. Use of iv. valproate sodium in status migraine
67. Intravenous valproate sodium (depacone) aborts migraine rapidly: A preliminary report
68. Valproate-associated pancreatitis
69. Pancreatitis in children on chronic dialysis treated with valproic acid
70. Valproic acid hepatic fatalities. III. US experience since 1986
71. Valproate metabolites in high dose valproate plus phenytoin therapy
72. Hematologic manifestation of long-term valproate therapy
73. Reversible cortical atrophy and cognitive decline induced by valproic acid
74. Reversible pseudoatrophy of brain and mental deterioration associated with valproate treatment
75. Valproic acid-induced hyperammonic encephalopathy with triphasic waves
76. Effect of carbamazepine and valproate on bone mineral density
77. Valproate and the polycystic ovarian syndrome. Final thoughts
78. Polycystic ovary syndrome in patients with focal epilepsy: A study in 93 women
79. On the association between valproate and Polycystic Ovary Syndrome
80. Effect of valproate, Phenobarbital and carbamazepine on sex steroid set-up in women with epilepsy
81. Weight gain with valproate in childhood
82. Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin
83. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics
84. Sodium valproate and oral contraceptive steroids
85. Sodium valproate monotherapy in childhood epilepsy
86. Phenobarbithal primidone and sodium valproate in prophylaxis in febrile convulsions
87. Effectivness and toxisity of phenobarbital, primidone in the prevention of febrile convulsions, controlled by plasma levels
88. Maternal valproic acid and congenital neural tube defects
89. The fetal valproate syndrome
90. Additional educational needs in children born to mothers with epilepsy
91. Placebo-controlled study of divalproex sodium for agitation in dementia
92. Evaluation and management of aggressive behavior in the elderly demented adult
93. Valproate plasma protein binding in the uremic condition
94. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease
95. Protein binding of valproic acid in uremic patients
96. Disposition of valproic acid in patients with liver disease
97. The effect of valproic acid on 5-hydroxytriptamine and 5 hydroxy-indoleacetic acid concentration in hippocampal dyalisates in vivo
98. Depression in epilepsy: A common but often unrecognized comorbid malady
99. Valproate prevents epileptiform activity after trauma in an in vitro model in neocortical slices
100. Valproate therapy for prevention of post traumatic seizures. A randomized trial